This printed article is located at https://investor.ouelh.com/news.html
|Announcement Title||Change - Announcement of Cessation|
|Date & Time of Broadcast||Oct 14, 2021 17:27|
|Announcement Sub Title||RESIGNATION OF INDEPENDENT AND NON-EXECUTIVE DIRECTOR|
|Submitted By (Co./ Ind. Name)||Mr. Yet Kum Meng|
|Designation||Chief Executive Officer and Executive Director|
|Description (Please provide a detailed description of the event in the box below)||Resignation of Mr. Johji Sato as Independent and Non-Executive Director.
This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.
The contact person for the Sponsor is Ms. Foo Jien Jieng, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, email@example.com.
|Name Of Person||Johji Sato|
|Is effective date of cessation known?||Yes|
|If yes, please provide the date||30/10/2021|
|Detailed Reason (s) for cessation||Mr. Johji Sato ("Mr. Sato") had, on 10 October 2021, tendered his resignation as Independent and Non-Executive Director of OUE Lippo Healthcare Limited (the "Company" and together with its subsidiaries, the "Group"), to pursue other interests and return to Japan to spend more time with his family as he moves into another phase of his life.
Mr. Sato's notice period is 20 days from 10 October 2021.
After having interviewed Mr. Sato and to the best of its knowledge, the Company's Sponsor, PrimePartners Corporate Finance Pte. Ltd., is satisfied that save as disclosed in this announcement, there are no other material reasons for the resignation of Mr. Sato as Independent and Non-Executive Director of the Company.
|Are there any unresolved differences in opinion on material matters between the person and the board of directors, including matters which would have a material impact on the group or its financial reporting?||No|
|Is there any matter in relation to the cessation that needs to be brought to the attention of the shareholders of the listed issuer?||No|
|Any other relevant information to be provided to shareholders of the listed issuer?||No|
|Date of Appointment to current position||15/02/2018|
|Does the AC have a minimum of 3 members (taking into account this cessation)?||Yes|
|Number of Independent Directors currently resident in Singapore (taking into account this cessation)||2|
|Number of cessations of appointments specified in Listing Rule 704 (7) or Catalist Rule 704 (6) over the past 12 months||1|
|Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)||Independent and Non-Executive Director, a member of the Audit and Risk Committee of the Company.|
|Role and responsibilities||The role and responsibilities as an Independent and Non-Executive Director, a member of the Audit and Risk Committee of the Company.|
|Familial relationship with any director and/ or substantial shareholder of the listed issuer or of any of its principal subsidiaries||Nil.|
|Shareholding interest in the listed issuer and its subsidiaries?||No|
|Past (for the last 5 years)||SUMIDA Corporation|
|Present||OUE Lippo Healthcare Limited|